ARIAD Pharmaceuticals (ARIA) Receives ‘Analyst’ Rating

ARIAD Pharmaceuticals (ARIA) has an average broker rating of 2, which is interpreted as a Buy, as rated by 4 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

ARIAD Pharmaceuticals (ARIA) : The highest short term price target forecast on ARIAD Pharmaceuticals (ARIA) is $13 and the lowest target price is $9. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $11 with a standard deviation of $1.83.


Also, Equity Analysts at the Barclays maintains the rating on ARIAD Pharmaceuticals (NASDAQ:ARIA). The brokerage firm has issued a Underweight rating on the shares. The Analysts at the ratings agency raises the price target from $8 per share to $9 per share. The rating by the firm was issued on July 29, 2016.

ARIAD Pharmaceuticals (NASDAQ:ARIA): After opening at $11.29, the stock dipped to an intraday low of $11.08 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $11.79 and the buying power remained strong till the end. The stock closed at $11.7 for the day, a gain of 6.27% for the day session. The total traded volume was 6,425,801. The stocks close on the previous trading day was $11.01.

ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.